BUHLMANN News

Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to

Continue Reading

Visit BUHLMANN Diagnostics Corp at AACC 2016

When: July 31 - August 4, 2016 Where: Philadelphia, PA Booth: #4202 Learn More: AACC 2016
Continue Reading

BÜHLMANN GanglioCombi™ MAG ELISA Utilized in Guillain-Barré Syndrome (GBS) and Zika Virus Study

The BÜHLMANN GanglioCombi™ MAG ELISA was recently utilized in a case-control study in French Polynesia focusing on individuals diagnosed with Guillain-Barré Syndrome (GBS). See publication below: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Learn More BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures in
Continue Reading

Connect with BUHLMANN Diagnostics Corp at MGCC 2016!

When: June 18 - 22, 2016 Where: Edmonton, AB Canada Booth: #307   More Information: Joint Conference of the Canadian College of Medical Geneticists and the Canadian Society of Clinical Chemists (MGCC 2016)
Continue Reading

Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays measuring the direct activity of compounds are limited because they do not provide information about the entire pathway controlled by these kinases. If you are interested in learning
Continue Reading

New Health Canada License for BÜHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo Speed, Quality and Flexibility in Calprotectin Quantification BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that its innovative product, BÜHLMANN fCAL® turbo, has received a Medical Device License from Health Canada and is now commercially available in Canada.  The device was approved as a Class 2
Continue Reading

Connect with BUHLMANN Diagnostics Corp (BDC) at DDW 2016

When: May 21-24, 2016 Where: San Diego, California Booth: #4155 More Information: Digestive Disease Week (DDW) 2016
Continue Reading

Calprotectin Video from Canadian Digestive Health Foundation (CDHF)

The Canadian Digestive Health Foundation (CDHF) has recently produced a very interesting video about the use of calprotectin to confirm and predict flares in inflammatory bowel disease patients and how it can be used to manage IBD.

Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2016

When: February 26 - 29, 2016 Where: Montreal, Quebec, Canada - Fairmont Queen Elizabeth Hotel' Booth: #1050 More Information Canadian Digestive Diseases Week
Continue Reading

Random Access Immuno Turbidimetric Faecal Calprotectin Assay

In autumn 2015 BÜHLMANN will launch a new generation of faecal calprotectin assay. The BÜHLMANN fCAL™turbo, the next step in automation of faecal calprotectin quantification used for Research Use Only. Fecal calprotectin (fCAL) is the most important marker in the study of gut inflammation. fCAL testing today demands for a raised level of lab resources including

Continue Reading